DNX Biopharmaceuticals Announces Collaboration with Lung Cancer Initiative at Johnson & Johnson
DNX Biopharmaceuticals, a biopharmaceutical company developing long-acting therapeutic proteins for the treatment of patients with life-long diseases and a resident of Johnson & Johnson Innovation – JLABS @ Shanghai, announced…